

Monomethyl auristatin E

Catalog No: tcsc0837



Available Sizes

Size: 1mg

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg

Size: 500mg

Size: 1g



Specifications

CAS No:

474645-27-7

Formula:

$C_{39}H_{67}N_5O_7$

Pathway:

Cell Cycle/DNA Damage;Cytoskeleton;Antibody-drug Conjugate/ADC Related

Target:

Microtubule/Tubulin;Microtubule/Tubulin;ADC Cytotoxin

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 48 mg/mL (66.85 mM)

Alternative Names:

Vedotin; MMAE

Observed Molecular Weight:

717.98


Product Description

Monomethyl auristatin E (MMAE) is a synthetic derivative of dolastatin 10 and functions as a potent **mitotic** inhibitor by inhibiting tubulin polymerization. MMAE is widely used as a cytotoxic component of **antibody-drug conjugates (ADCs)** to treat several different cancer types.

IC50 & Target: Microtubule^[1]

In Vitro: Monomethyl auristatin E (MMAE) is efficiently released from SGN-35 within CD30⁺ cancer cells and, due to its membrane permeability, is able to exert cytotoxic activity on bystander cells^[1]. MMAE sensitizes colorectal and pancreatic cancer cells to IR in a schedule and dose dependent manner correlating with mitotic arrest. Radiosensitization is evidenced by decreased clonogenic survival and increased DNA double strand breaks in irradiated cells^[2].

In Vivo: Monomethyl auristatin E (MMAE) in combination with IR results in tumor growth delay, tumor-targeted ACPD-cRGD-MMAE with IR produces a more robust and significantly prolongs tumor regression in xenograft models^[2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!